Cargando…
Regulatory Agencies and PET/CT Imaging in the Clinic
PURPOSE OF REVIEW: The regulatory steps necessary to bring new PET radiopharmaceuticals to the clinic will be reviewed. The US Food and Drug Administration (FDA) provides approval to manufacture and use diagnostic radiopharmaceuticals, including those for cardiovascular PET/CT. Medicare not only pro...
Autor principal: | Herscovitch, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340745/ https://www.ncbi.nlm.nih.gov/pubmed/35913674 http://dx.doi.org/10.1007/s11886-022-01749-7 |
Ejemplares similares
-
Molecular Imaging Using Cardiac PET/CT: Opportunities to Harmonize Diagnosis and Therapy
por: Thackeray, James T.
Publicado: (2021) -
PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity
por: Sivapackiam, Jothilingam, et al.
Publicado: (2020) -
PET Imaging of Post-infarct Myocardial Inflammation
por: Ćorović, Andrej, et al.
Publicado: (2021) -
PET Tracers for Imaging Cardiac Function in Cardio-oncology
por: Kelly, James M., et al.
Publicado: (2022) -
PET Imaging of the Human Nicotinic Cholinergic Pathway in Atherosclerosis
por: Bauwens, Matthias, et al.
Publicado: (2015)